Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMAO), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.
XOMA Royalty Corporation (XOMAO) provides investors and industry observers with comprehensive access to official company announcements and market-moving developments. This dedicated news hub tracks the biotechnology royalty aggregator's licensing agreements, milestone achievements, and strategic partnerships that shape its unique financial model.
Our curated collection of XOMA press releases and verified news coverage offers critical insights into the company's portfolio growth and revenue-generating activities. Users gain centralized access to updates on therapeutic candidate progress, regulatory milestones, and financial performance directly tied to XOMA's royalty aggregation strategy.
The page features essential updates including earnings reports, new licensing agreements, clinical trial milestones, and partnership expansions. All content is verified for accuracy and timeliness to support informed decision-making about this specialized biotech investment vehicle.
Bookmark this page for streamlined tracking of XOMA's evolving role in pharmaceutical financing. Check regularly for updates on how the company's royalty interests in antibody therapeutics and innovative treatments translate into financial performance.
XOMA Royalty reported its Q4 and full year 2024 financial results, highlighting significant portfolio expansion and business achievements. The company doubled its royalty and milestone portfolio to over 120 assets through five transactions in 2024, including two whole company acquisitions.
Key financial metrics include:
- Q4 cash receipts: $4.0 million
- Full-year cash receipts: $46.3 million
- Q4 total income: $8.7 million
- Full-year total income: $28.5 million
- Year-end cash position: $106.4 million
Notable developments include FDA approvals for Day One's OJEMDA™ and Zevra's MIPLYFFA™. The company deployed $65 million to acquire new milestone and royalty assets and paid $5.5 million in dividends. However, XOMA recorded a net loss of $4.0 million in Q4 and $13.8 million for the full year 2024, primarily due to $30.9 million in non-cash credit losses on purchased receivables.
XOMA Royalty (NASDAQ: XOMA), a biotech royalty aggregator, has announced its Executive Team's upcoming participation in investor conferences scheduled for March 2025. The company will engage in one-on-one investor meetings during these events.
Presentations will be accessible through the investor relations section of XOMA's website (www.xoma.com). Each presentation will remain archived and available for replay on the site for a 90-day period following the respective events.
XOMA Royalty (NASDAQ: XOMA) has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference, scheduled for February 11-12, 2025. The virtual event will feature a fireside chat with CEO Owen Hughes and CIO Brad Sitko on February 11, 2025, at 3:20 PM ET.
The presentation will be accessible through a dedicated link and through XOMA's investor relations website section. Interested parties can access the replay of the presentation, which will remain archived on the company's website for 90 days following the event.
XOMA Royalty (Nasdaq: XOMA) has announced quarterly cash dividends for its preferred stockholders. The company will distribute $0.53906 per share to holders of 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) and $0.52344 per depositary share to holders of 8.375% Series B Cumulative Perpetual Preferred Stock (XOMAO). Both dividends will be paid on January 15, 2025, to shareholders of record as of January 3, 2025.
XOMA Royalty has acquired Pulmokine for $20 million, gaining rights to seralutinib, a Phase 3 asset being developed for pulmonary arterial hypertension (PAH). The acquisition adds seralutinib as XOMA's seventh Phase 3 royalty asset, complementing its six commercial royalty assets. Seralutinib is being co-developed by Gossamer Bio and Chiesi Farmaceutici, with Phase 3 study results expected in Q4 2025. Through this acquisition, XOMA stands to receive up to $25 million in milestone payments and earn a low to mid-single digit royalty on commercial sales.
XOMA Royalty reported Q3 2024 financial results with total income of $7.2 million, including $6.5 million from commercial products. Cash receipts totaled $9.9 million in Q3 and $42.3 million for the first nine months of 2024. The company recorded a net loss of $17.2 million, primarily due to a $14.0 million non-cash impairment related to Agenus. Notable events include FDA approval of MIPLYFFA™ for Niemann-Pick disease Type C and acquisition of 50% economic interest in TWIST Bioscience's portfolio of 60-plus licensed early-stage assets. Cash position stood at $146.8 million as of September 30, 2024.
XOMA Royalty announced that Zevra Therapeutics has received FDA approval for MIPLYFFA™ (arimoclomol), the first therapy approved for use in patients with Niemann-Pick Disease Type C (NPC). MIPLYFFA™ is approved for use in combination with miglustat to treat neurological manifestations of NPC in patients two years and older.
XOMA Royalty is entitled to receive a mid-single digit royalty on MIPLYFFA™ sales and up to $52.6 million in milestones. This approval marks MIPLYFFA™ as the sixth commercial asset in XOMA Royalty's portfolio. In June 2023, XOMA Royalty acquired these rights from LadRx for a $5 million upfront payment plus a share of future event-based milestones.
XOMA Royalty (Nasdaq: XOMA) has announced quarterly cash dividends for its Series A and Series B Cumulative Preferred Stock. Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) will receive $0.53906 per share. Holders of depositary shares for the 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO) will receive $0.52344 per depositary share. The dividends will be paid on or about October 15, 2024, to holders of record as of the close of business on October 3, 2024. This announcement demonstrates XOMA's commitment to providing returns to its preferred stockholders.
XOMA Royalty (NASDAQ: XOMA), a biotech royalty aggregator, has announced its participation in two major investor conferences in September 2024. The company's executive team, including CEO Owen Hughes and CIO Brad Sitko, will present corporate overviews at:
1. The H.C. Wainwright 26th Annual Global Investment Conference in New York, NY (September 9-11, 2024). Presentation scheduled for September 9 at 9:00 AM ET.
2. The 2024 Cantor Global Healthcare Conference in New York, NY (September 17-19, 2024). Presentation scheduled for September 17 at 2:30 PM ET.
Both presentations will be accessible via provided links and through XOMA's investor relations website. Replays will be available for 90 days after each event.
XOMA Royalty (NASDAQ: XOMA) reported its second quarter 2024 financial results and highlighted recent activities. Key points include:
- Cash receipts totaled $22.6 million in Q2 2024, including royalty income and milestones
- Expanded commercial royalty portfolio with acquisition of interests in XACIATO™ and two Phase 3 assets
- Completed acquisition of Kinnate Pharmaceuticals, adding potential royalty streams and over $9.5 million in capital
- FDA approved Day One's OJEMDA™, becoming XOMA's fifth commercial royalty
- Recorded total income and revenues of $11.1 million for Q2 2024
- Reported net income of $16.0 million for Q2 2024, compared to a net loss of $5.4 million in Q2 2023
- Cash and cash equivalents of $149.9 million as of June 30, 2024
FAQ
What is the current stock price of XOMA Royalty Corporation (XOMAO)?
